Literature DB >> 31560740

Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.

B Popovic-Todorovic1, S Santos-Ribeiro1,2, P Drakopoulos1, M De Vos1, A Racca1, S Mackens1, Y Thorrez1, G Verheyen1, H Tournaye1, L Quintero3, C Blockeel1.   

Abstract

STUDY QUESTION: Are the LH levels at the start of ovarian stimulation predictive of suboptimal oocyte yield from GnRH agonist triggering in GnRH antagonist down-regulated cycles? SUMMARY ANSWER: LH levels at the start of ovarian stimulation are an independent predictor of suboptimal oocyte yield following a GnRH agonist trigger. WHAT IS KNOWN ALREADY: A GnRH agonist ovulation trigger may result in an inadequate oocyte yield in a small subset of patients. This failure can range from empty follicle syndrome to the retrieval of much fewer oocytes than expected. Suboptimal response to a GnRH agonist trigger has been defined as the presence of circulating LH levels <15 IU/l 12 h after triggering. It has been shown that patients with immeasurable LH levels on trigger day have an up to 25% risk of suboptimal response. STUDY DESIGN, SIZE, DURATION: In this retrospective cohort study, all patients (n = 3334) who received GnRH agonist triggering (using Triptoreline 0.2 mg) for final oocyte maturation undergoing a GnRH antagonist cycle in our centre from 2011 to 2017 were included. The primary outcome of the study was oocyte yield, defined as the ratio between the total number of collected oocytes and the number of follicles with a mean diameter >10 mm prior to GnRH agonist trigger. PARTICIPANTS/MATERIALS, SETTING,
METHODS: The endocrine profile of all patients was studied at initiation as well as at the end of ovarian stimulation. In order to evaluate whether LH levels, not only at the end but also at the start, of ovarian stimulation predicted oocyte yield, we performed multivariable regression analysis adjusting for the following confounding factors: female age, body mass index, oral contraceptives before treatment, basal and trigger day estradiol levels, starting FSH levels, use of highly purified human menopausal gonadotrophin and total gonadotropin dose. Suboptimal response to GnRH agonist trigger was defined as <10th percentile of oocyte yield. MAIN RESULTS AND THE ROLE OF CHANCE: The average age was 31.9 years, and the mean oocyte yield was 89%. The suboptimal response to GnRH agonist trigger cut-off (<10th percentile) was 45%, which was exhibited by 340 patients. Following confounder adjustment, multivariable regression analysis showed that LH levels at the initiation of ovarian stimulation remained an independent predictor of suboptimal response even in the multivariable model (adjusted OR 0.920, 95% CI 0.871-0.971). Patients with immeasurable LH levels at the start of stimulation (<0.1 IU/l) had a 45.2% risk of suboptimal response, while the risk decreased with increasing basal LH levels; baseline circulating LH <0.5 IU/L, <2 IU/L and <5 IU/L were associated with a 39.1%, 25.2% and 13.6% risk, respectively. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the study is its retrospective design. WIDER IMPLICATIONS OF THE
FINDINGS: This is the largest study of GnRH agonist trigger cycles only, since most of the previous research on the predictive value of basal LH levels was performed in dual trigger cycles. LH values should be measured prior to start of ovarian stimulation. In cases where they are immeasurable, suboptimal response to GnRH agonist trigger can be anticipated, and an individualized approach is warranted. STUDY FUNDING/COMPETING INTEREST(S): There was no funding and no competing interests. TRIAL REGISTRATION NUMBER: Not applicable.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  GnRH agonist trigger; LH level at start of stimulation; luteinizing hormone; oocyte yield; ovarian stimulation; suboptimal response

Year:  2019        PMID: 31560740     DOI: 10.1093/humrep/dez132

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

Review 1.  Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Authors:  Hadas Ganer Herman; Eran Horowitz; Yossi Mizrachi; Jacob Farhi; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2022-03-19       Impact factor: 3.412

2.  Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles.

Authors:  Hiroya Kitasaka; Mikiko Tokoro; Masae Kojima; Noritaka Fukunaga; Yoshimasa Asada
Journal:  Reprod Med Biol       Date:  2020-12-18

3.  Follicular phase cycle programming using estradiol in oocyte donors-a convenient and effective approach.

Authors:  Manish Banker; Parul Arora; Jwal Banker; Reena Gupta; Sandeep Shah
Journal:  F S Rep       Date:  2022-01-05

Review 4.  Agonist triggering in oocyte donation programs-Mini review.

Authors:  Robert Najdecki; Georgios Michos; Nikos Peitsidis; Evangelia Timotheou; Tatiana Chartomatsidou; Stelios Kakanis; Foteini Chouliara; Apostolos Mamopoulos; Evangelos Papanikolaou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-26       Impact factor: 6.055

5.  Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.

Authors:  Ali Abbara; Tia Hunjan; Vu N A Ho; Sophie A Clarke; Alexander N Comninos; Chioma Izzi-Engbeaya; Tuong M Ho; Geoffrey H Trew; Artsiom Hramyka; Tom Kelsey; Rehan Salim; Peter Humaidan; Lan N Vuong; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-06       Impact factor: 5.555

6.  Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination.

Authors:  Y Bentov; O Beharier; A Moav-Zafrir; M Kabessa; M Godin; C S Greenfield; M Ketzinel-Gilad; E Ash Broder; H E G Holzer; D Wolf; E Oiknine-Djian; I Barghouti; D Goldman-Wohl; S Yagel; A Walfisch; A Hersko Klement
Journal:  Hum Reprod       Date:  2021-08-18       Impact factor: 6.918

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.